Therefore, we suggest that PD-L1 immunotherapy, singly or in combination with a YAP1 inhibitor, may not only reduce tumor aggressiveness but it could also overcome TKI resistance in NSCLC, particularly in patients with tumors that express both PD-L1 and YAP1. The gene discussed is YAP1; the disease is neoplasm.